Monte Rosa Therapeutics (GLUE.US) Officer Plans to Sell $103.45 Million in Common Stock via Form 144
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Should l Buy GLUE?
Source: moomoo
Stock Sale Announcement: Warmuth Markus intends to sell 5,467 shares of Monte Rosa Therapeutics (GLUE.US) on May 1, with an estimated market value of approximately $103.45 million.
Reduction in Shareholding: Since March 2, 2026, Warmuth Markus has reduced his shareholding in Monte Rosa Therapeutics by 13,466 shares, valued at around $239.1K.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLUE
Wall Street analysts forecast GLUE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.810
Low
20.00
Averages
30.40
High
37.00
Current: 19.810
Low
20.00
Averages
30.40
High
37.00
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Monte Rosa Therapeutics (GLUE.US) Officer Plans to Sell $103.45 Million in Common Stock via Form 144
Stock Sale Announcement: Warmuth Markus intends to sell 5,467 shares of Monte Rosa Therapeutics (GLUE.US) on May 1, with an estimated market value of approximately $103.45 million.
Reduction in Shareholding: Since March 2, 2026, Warmuth Markus has reduced his shareholding in Monte Rosa Therapeutics by 13,466 shares, valued at around $239.1K.
See More
Monte Rosa Therapeutics CEO Sells Shares Amid Strong Market Performance
- Executive Share Sale: Monte Rosa Therapeutics CEO Markus Warmuth sold 8,000 shares on April 14, 2026, for $141,124.80, reflecting insider liquidity needs amid a 300% stock price surge.
- Transaction Scale Comparison: This sale marks Warmuth's largest since January 2026, surpassing two prior sales of 5,466 shares each, indicating a consistent pattern of liquidity events.
- Ownership Analysis: Post-transaction, Warmuth retains 605,471 shares valued at approximately $10.60 million, demonstrating continued confidence in the company despite a decrease in insider ownership to 0.93%.
- Strong Financial Position: By the end of 2025, the company had around $382 million in cash and raised an additional $345 million in equity, ensuring funding through 2029 to support its clinical trial advancements.
See More
Monte Rosa Therapeutics Reports Q4 Loss and Revenue Decline
- Widening Net Loss: Monte Rosa Therapeutics reported a net loss of $46.1 million in Q4 2025, significantly up from $13.4 million in Q4 2024, indicating challenges in financial management and cost control.
- Revenue Plummets: The company's revenue for the fourth quarter was $2.78 million, a staggering 95.4% year-over-year decline, missing expectations by $12.73 million, reflecting weak market demand and poor product sales performance.
- Collaboration Revenue Decline: Collaboration revenue for Q4 2025 was $2.8 million, down from $60.6 million in Q4 2024, with total collaboration revenue for the year at $123.7 million, up from $75.6 million in 2024, yet indicating diminishing returns from partnerships with Roche and Novartis.
- Market Reaction: Although the collaboration with Johnson & Johnson for cancer therapy trials has garnered some market interest, the ongoing deterioration in financial performance may negatively impact investor confidence, limiting further stock price appreciation.
See More
Agenus Surpasses Earnings and Revenue Expectations
- Earnings Beat: Agenus reported earnings of $0.56 per share, significantly exceeding the Zacks consensus estimate of a loss of $1.27 per share, and improving from a loss of $2.04 per share a year ago, indicating a strong recovery in profitability that is likely to boost investor confidence.
- Significant Revenue Growth: The company posted revenues of $34.2 million for the quarter, surpassing the Zacks consensus estimate of $29.3 million and reflecting a 27.5% increase from $26.84 million a year ago, demonstrating sustained market demand in the biopharmaceutical sector.
- Cautious Future Outlook: Although Agenus has surpassed consensus EPS estimates twice in the past four quarters, management's commentary on future earnings expectations will be crucial for stock price movements; currently, the Zacks Rank is 3 (Hold), suggesting performance may align with the market in the near term.
- Industry Ranking Impact: The Medical - Biomedical and Genetics industry, where Agenus operates, is currently ranked in the bottom 42% by Zacks, which could negatively affect the company's stock performance, prompting investors to monitor overall industry trends for potential impacts on future performance.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for MRT-2359
- Clinical Trial Collaboration: Monte Rosa Therapeutics has signed a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA for the treatment of metastatic castration-resistant prostate cancer, with a new Phase 2 study expected to start in Q3 2026, indicating the company's strategic positioning in prostate cancer treatment.
- Drug Combination Research: MRT-2359, an orally bioavailable molecular glue degrader, will be studied in 25 AR-mutant patients to assess its efficacy and safety alongside ERLEADA, with potential expansion to other patient subsets if results are positive, reflecting the company's confidence in new therapeutic options.
- Financial Performance: As of September 30, 2025, Monte Rosa reported collaboration revenue of $12.8 million, a 39% increase from $9.2 million in the prior year, despite a net loss widening to $27.1 million, showcasing the company's ongoing investment in R&D and market expansion.
- Stock Performance: Following this announcement, GLUE's stock rose 4.74% to $16.78, reflecting market optimism regarding its collaboration with Johnson & Johnson, with the stock trading between $3.50 and $25.77 over the past year, indicating investor interest in its future potential.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for Cancer Treatment
- Supply Agreement Established: Monte Rosa Therapeutics (GLUE) has signed a supply agreement with Johnson & Johnson (JNJ) to evaluate MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) patients, marking a strategic collaboration in cancer treatment.
- Clinical Trial Plans: Under the agreement, Monte Rosa will conduct and sponsor the trial, planning to initiate a signal-confirming phase 2 study targeting AR mutant patients in Q3 2026, with an expected enrollment of up to 25 patients to efficiently assess the efficacy and safety of MRT-2359 plus ERLEADA.
- Positive Market Reaction: Following the announcement, Monte Rosa's shares rose by 1.6% to $16.28, reflecting market optimism regarding the new research direction and potentially boosting investor confidence.
- Research Evaluation Metrics: The study will evaluate key metrics including PSA response, RECIST response, duration of response, progression-free survival (PFS), and safety, with the potential to expand to other patient subsets if activity in the AR mutant population is confirmed.
See More
Monte Rosa Therapeutics (GLUE.US) Officer Plans to Sell $103.45 Million in Common Stock via Form 144
Stock Sale Announcement: Warmuth Markus intends to sell 5,467 shares of Monte Rosa Therapeutics (GLUE.US) on May 1, with an estimated market value of approximately $103.45 million.
Reduction in Shareholding: Since March 2, 2026, Warmuth Markus has reduced his shareholding in Monte Rosa Therapeutics by 13,466 shares, valued at around $239.1K.
See More
Monte Rosa Therapeutics CEO Sells Shares Amid Strong Market Performance
- Executive Share Sale: Monte Rosa Therapeutics CEO Markus Warmuth sold 8,000 shares on April 14, 2026, for $141,124.80, reflecting insider liquidity needs amid a 300% stock price surge.
- Transaction Scale Comparison: This sale marks Warmuth's largest since January 2026, surpassing two prior sales of 5,466 shares each, indicating a consistent pattern of liquidity events.
- Ownership Analysis: Post-transaction, Warmuth retains 605,471 shares valued at approximately $10.60 million, demonstrating continued confidence in the company despite a decrease in insider ownership to 0.93%.
- Strong Financial Position: By the end of 2025, the company had around $382 million in cash and raised an additional $345 million in equity, ensuring funding through 2029 to support its clinical trial advancements.
See More
Monte Rosa Therapeutics Reports Q4 Loss and Revenue Decline
- Widening Net Loss: Monte Rosa Therapeutics reported a net loss of $46.1 million in Q4 2025, significantly up from $13.4 million in Q4 2024, indicating challenges in financial management and cost control.
- Revenue Plummets: The company's revenue for the fourth quarter was $2.78 million, a staggering 95.4% year-over-year decline, missing expectations by $12.73 million, reflecting weak market demand and poor product sales performance.
- Collaboration Revenue Decline: Collaboration revenue for Q4 2025 was $2.8 million, down from $60.6 million in Q4 2024, with total collaboration revenue for the year at $123.7 million, up from $75.6 million in 2024, yet indicating diminishing returns from partnerships with Roche and Novartis.
- Market Reaction: Although the collaboration with Johnson & Johnson for cancer therapy trials has garnered some market interest, the ongoing deterioration in financial performance may negatively impact investor confidence, limiting further stock price appreciation.
See More
Agenus Surpasses Earnings and Revenue Expectations
- Earnings Beat: Agenus reported earnings of $0.56 per share, significantly exceeding the Zacks consensus estimate of a loss of $1.27 per share, and improving from a loss of $2.04 per share a year ago, indicating a strong recovery in profitability that is likely to boost investor confidence.
- Significant Revenue Growth: The company posted revenues of $34.2 million for the quarter, surpassing the Zacks consensus estimate of $29.3 million and reflecting a 27.5% increase from $26.84 million a year ago, demonstrating sustained market demand in the biopharmaceutical sector.
- Cautious Future Outlook: Although Agenus has surpassed consensus EPS estimates twice in the past four quarters, management's commentary on future earnings expectations will be crucial for stock price movements; currently, the Zacks Rank is 3 (Hold), suggesting performance may align with the market in the near term.
- Industry Ranking Impact: The Medical - Biomedical and Genetics industry, where Agenus operates, is currently ranked in the bottom 42% by Zacks, which could negatively affect the company's stock performance, prompting investors to monitor overall industry trends for potential impacts on future performance.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for MRT-2359
- Clinical Trial Collaboration: Monte Rosa Therapeutics has signed a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA for the treatment of metastatic castration-resistant prostate cancer, with a new Phase 2 study expected to start in Q3 2026, indicating the company's strategic positioning in prostate cancer treatment.
- Drug Combination Research: MRT-2359, an orally bioavailable molecular glue degrader, will be studied in 25 AR-mutant patients to assess its efficacy and safety alongside ERLEADA, with potential expansion to other patient subsets if results are positive, reflecting the company's confidence in new therapeutic options.
- Financial Performance: As of September 30, 2025, Monte Rosa reported collaboration revenue of $12.8 million, a 39% increase from $9.2 million in the prior year, despite a net loss widening to $27.1 million, showcasing the company's ongoing investment in R&D and market expansion.
- Stock Performance: Following this announcement, GLUE's stock rose 4.74% to $16.78, reflecting market optimism regarding its collaboration with Johnson & Johnson, with the stock trading between $3.50 and $25.77 over the past year, indicating investor interest in its future potential.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for Cancer Treatment
- Supply Agreement Established: Monte Rosa Therapeutics (GLUE) has signed a supply agreement with Johnson & Johnson (JNJ) to evaluate MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) patients, marking a strategic collaboration in cancer treatment.
- Clinical Trial Plans: Under the agreement, Monte Rosa will conduct and sponsor the trial, planning to initiate a signal-confirming phase 2 study targeting AR mutant patients in Q3 2026, with an expected enrollment of up to 25 patients to efficiently assess the efficacy and safety of MRT-2359 plus ERLEADA.
- Positive Market Reaction: Following the announcement, Monte Rosa's shares rose by 1.6% to $16.28, reflecting market optimism regarding the new research direction and potentially boosting investor confidence.
- Research Evaluation Metrics: The study will evaluate key metrics including PSA response, RECIST response, duration of response, progression-free survival (PFS), and safety, with the potential to expand to other patient subsets if activity in the AR mutant population is confirmed.
See More
